Bosutinib is approved as first line therapy for treatment of chronic
phase CML and also in patients who are either resistant or intolerant to
previous TKI. We present a 59 year old male who was intolerant to 2 TKI
but showed excellent hematological and major molecular response to
Bosutinib.